Targeting specificity of dendritic cells on breast cancer stem cells: In vitro and in vivo evaluations

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 323-334

  Nguyen, Sinh Truong ^a   Nguyen, Huyen Lam ^a   Pham, Viet Quoc ^a   Nguyen, Giang Thuy ^a   Do Thanh Tran, Cuong ^a   Phan, Ngoc Kim ^a,b   Van Pham, Phuc ^a,b  

^a VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^b UNIVERSITY OF NATURAL SCIENCES   (Viet Nam)

Author keywords

4T1 cell line; Breast cancer stem cells; Breast tumor; Dendritic cells; Drug resistance; Verapamil

Indexed keywords

5' NUCLEOTIDASE; CD45 ANTIGEN; ENDOGLIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 4; THY 1 ANTIGEN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; CELL THERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MONOCYTE; MOUSE; NONHUMAN; TARGET CELL DESTRUCTION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84961295543     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S77554     Document Type: Article

References (52)

1. Lan NH, Laohasiriwong W, Stewart JF. Survival probability and prognostic factors for breast cancer patients in Vietnam. Glob Health Action. 2013;6:1-9.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-3988.
4. Modrek AS, Bayin NS, Placantonakis DG. Brain stem cells as the cell of origin in glioma. World J Stem Cells. 2014;6(l):43-52.
5. Prasetyanti PR, Zimberlin C, De Sousa EMF, Medema JP. Isolation and propagation of colon cancer stem cells. Methods Mol Biol. 2013;1035:247-259.
6. Han J, Fujisawa T, Husain SR, Puri RK. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer. 2014;14:173.
7. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol. 2008; 14(24):3903-3907.
8. Luo Y, Nguyen N, Fujita M. Isolation of human melanoma stem cells using ALDH as a marker. Curr Protoc Stem Cell Biol. 2013;26: Unit 3.8.
9. Tomuleasa C, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 2010;19(1):61-67.
10. Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008;3(7):e2637.
11. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev. 2008;4(3):193-201.
12. O’Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;16(12):3113-3120.
13. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142-1162.
14. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999;1(6):362-368.
15. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995;375(6527):151-155.
16. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factorplus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109-1118.
17. Adema GJ, Hartgers F, Verstraten R, et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 1997; 387(6634):713-717.
18. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252.
19. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63(1):12-17.
20. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother. 1999;48(2-3):118-122.
21. Cody V, Shen H, Shlyankevich M, Tigelaar RE, Brandsma JL, Hanlon DJ. Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4. Vet Immunol Immunopathol. 2005;103(3-4):163-172.
22. Menges M, Baumeister T, Rossner S, et al. IL-4 supports the generation of a dendritic cell subset from murine bone marrow with altered endocytosis capacity. J Leukoc Biol. 2005;77(4):535-543.
23. [No authors listed]. Vaccine studies demonstrate promise of immunotherapy to treat breast cancer and prevent recurrence. Oncology. 2000;14(10):1415-1416.
24. Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine. 2011; 29(29-30):4785-4793.
25. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51(11-12):669-673.
26. Teitz-Tennenbaum S, Wicha MS, Chang AE, Li Q. Targeting cancer stem cells via dendritic-cell vaccination. Oncoimmunology. 2012; 1(8): 1401-1403.
27. Pham PV, Chi HJ, Nguyen NT, et al. Effects of breast cancer stem cell extract primed dendritic cell transplantation on breast cancer tumor murine models. Annu Rev Res Biol. 2011;1(1):1-13.
28. Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013; 62(9):1499-1509.
29. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4): 315-317.
30. Schuier T, Kammertoens T, Preiss S, Debs P, Noben-Trauth N, Blankenstein T. Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells. J Exp Med. 2001;194(12): 1767-1775.
31. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond). 2012;7(4):597-615.
32. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275-284.
33. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transi Med. 2013;2(1):3.
34. Rizzo S, Hersey JM, Mellor P, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011;10(2):325-335.
35. Calcagno AM, Salcido CD, Gillet JP, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010;102(21):1637-1652.
36. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 2008;3(8):e3077.
37. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:30.
38. Huber KR, Schmidt WF, Thompson EA, Forsthoefel AM, Neuberg RW, Ettinger RS. Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells. Br J Cancer. 1989;59(5):714-718.
39. Trompier D, Chang XB, Barattin R, du Moulinet D’Hardemare A, Di Pietro A, Baubichon-Cortay H. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res. 2004;64(14):4950-4956.
40. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105-127.
41. Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Archiv. 2007;453(5):661-673.
42. Van Phuc P, Nhan PL, Nhung TH, et al. Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther. 2011;4:71-78.
43. Pham PV, Phan NL, Nguyen NT, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transi Med. 2011;9:209.
44. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15(12):4234-4241.
45. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005;175(2):820-828.
46. Bai L, Beckhove P, Feuerer M, et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancerpatients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer. 2003; 103(1):73-83.
47. Sato M, Chamoto K, Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int Immunol. 2003;15(7):837-843.
48. Abdul Hafid SR, Chakravarthi S, Nesaretnam K, Radhakrishnan AK. Tocotrienol-adjuvanted dendritic cells inhibit tumor growth and metastasis: a murine model of breast cancer. PLoS One. 2013;8(9):e74753.
49. Coveney E, Wheatley GH 3rd, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery. 1997;122(2):228-234.
50. Radhakrishnan AK, Sim GC, Cheong SK. Comparing the ability of freshly generated and cryopreserved dendritic cell vaccines to inhibit growth of breast cancer in a mouse model. Biores Open Access. 2012;1(5):239-246.
51. Engleman EG. Dendritic cells: potential role in cancer therapy. Cytotechnology. 1997;25(l-3):l-8.
52. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002;51(6):299-310.